Overview

Trial Evaluating the Efficacy and Safety of Perampanel Added to Monotherapy in Participants With Partial Onset Seizures With or Without Secondary Generalization

Status:
Completed
Trial end date:
2018-04-26
Target enrollment:
Participant gender:
Summary
This is a multi-center, open-label, single-arm, phase 4 study to evaluate the efficacy of perampanel added to monotherapy for partial onset seizures with or without secondarily generalized seizures (total seizures).
Phase:
Phase 4
Details
Lead Sponsor:
Eisai Korea Inc.